Technical Analysis for ALRN - Aileron Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
MACD Bearish Signal Line Cross | Bearish | 0.00% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Narrow Range Bar | Range Contraction | -3.05% | |
Wide Bands | Range Expansion | -3.05% | |
Inside Day | Range Contraction | -2.17% | |
Wide Bands | Range Expansion | -2.17% | |
Upper Bollinger Band Walk | Strength | -2.87% | |
Wide Bands | Range Expansion | -2.87% |
Alert | Time |
---|---|
Up 1% | about 16 hours ago |
Down 3% | about 18 hours ago |
Fell Below Previous Day's Low | about 18 hours ago |
Down 2 % | about 18 hours ago |
60 Minute Opening Range Breakdown | about 20 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 03/20/2024
Aileron Therapeutics, Inc. Description
Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Solid Tumors Tumor Molecular Biology Inflammation Lymphoma Cell Biology Metabolic Disease Peptides Oncogenes Hematological Malignancies Proteins P53 Tumor Suppressor Genes Treatment Of A Range Of Cancer Tumor Suppressor
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 6.12 |
52 Week Low | 1.01 |
Average Volume | 37,306 |
200-Day Moving Average | 2.55 |
50-Day Moving Average | 4.69 |
20-Day Moving Average | 5.17 |
10-Day Moving Average | 5.54 |
Average True Range | 0.40 |
RSI (14) | 56.52 |
ADX | 39.47 |
+DI | 25.76 |
-DI | 14.48 |
Chandelier Exit (Long, 3 ATRs) | 4.77 |
Chandelier Exit (Short, 3 ATRs) | 5.60 |
Upper Bollinger Bands | 5.99 |
Lower Bollinger Band | 4.35 |
Percent B (%b) | 0.65 |
BandWidth | 31.89 |
MACD Line | 0.28 |
MACD Signal Line | 0.29 |
MACD Histogram | -0.0093 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 5.86 | ||||
Resistance 3 (R3) | 5.90 | 5.78 | 5.78 | ||
Resistance 2 (R2) | 5.78 | 5.67 | 5.76 | 5.76 | |
Resistance 1 (R1) | 5.60 | 5.60 | 5.54 | 5.56 | 5.73 |
Pivot Point | 5.48 | 5.48 | 5.45 | 5.46 | 5.48 |
Support 1 (S1) | 5.30 | 5.37 | 5.24 | 5.26 | 5.09 |
Support 2 (S2) | 5.18 | 5.30 | 5.17 | 5.06 | |
Support 3 (S3) | 5.00 | 5.18 | 5.04 | ||
Support 4 (S4) | 4.96 |